HighPoint Advisor Group LLC Buys Shares of 10,817 GSK plc (NYSE:GSK)

HighPoint Advisor Group LLC purchased a new position in shares of GSK plc (NYSE:GSK) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 10,817 shares of the pharmaceutical company’s stock, valued at approximately $401,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Fisher Asset Management LLC grew its position in shares of GSK by 10.8% in the 4th quarter. Fisher Asset Management LLC now owns 15,065,558 shares of the pharmaceutical company’s stock worth $558,330,000 after acquiring an additional 1,465,165 shares in the last quarter. Primecap Management Co. CA grew its holdings in shares of GSK by 0.3% during the fourth quarter. Primecap Management Co. CA now owns 12,089,370 shares of the pharmaceutical company’s stock valued at $448,032,000 after purchasing an additional 30,600 shares during the last quarter. Royal Bank of Canada raised its position in shares of GSK by 5.1% during the 3rd quarter. Royal Bank of Canada now owns 8,079,897 shares of the pharmaceutical company’s stock worth $292,896,000 after purchasing an additional 389,871 shares during the period. Morgan Stanley lifted its holdings in shares of GSK by 2.1% in the 3rd quarter. Morgan Stanley now owns 7,551,555 shares of the pharmaceutical company’s stock worth $273,744,000 after purchasing an additional 156,480 shares during the last quarter. Finally, Provident Trust Co. boosted its position in GSK by 53.6% during the 4th quarter. Provident Trust Co. now owns 3,716,830 shares of the pharmaceutical company’s stock valued at $137,746,000 after purchasing an additional 1,297,385 shares during the period. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Down 0.5 %

NYSE GSK opened at $40.76 on Friday. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. The company has a market capitalization of $84.47 billion, a P/E ratio of 14.77, a PEG ratio of 1.24 and a beta of 0.66. GSK plc has a 12 month low of $33.67 and a 12 month high of $45.92. The company’s 50 day simple moving average is $42.56 and its 200 day simple moving average is $41.03.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, beating the consensus estimate of $0.94 by $0.15. GSK had a net margin of 14.62% and a return on equity of 51.54%. The business had revenue of $9.34 billion during the quarter, compared to the consensus estimate of $8.98 billion. Equities research analysts expect that GSK plc will post 4.11 earnings per share for the current fiscal year.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be given a dividend of $0.3762 per share. This represents a $1.50 annualized dividend and a yield of 3.69%. This is a positive change from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. GSK’s payout ratio is presently 53.26%.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on GSK shares. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. The Goldman Sachs Group initiated coverage on GSK in a report on Thursday, May 30th. They issued a “neutral” rating and a $47.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.00.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.